Primary Biliary Cholangitis
Investigators
Open Research Studies for Primary Biliary Cholangitis
Cara PBC
Enrolling: Yes
Principle Investigator: Raj Vuppalanchi, MD
Duration: 21 weeks
Patient Population: Patients with moderate to severe itching.
Drug(s): Oral CR845
Interested in this study? Please contact the coordinator below:
Mandy Cruz
mandcruz@iu.edu
(317) 278-6215
TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
Principle Investigator: Raj Vuppalanchi, MD
Duration: 120 weeks
Patient Population: Patients over the age of 18 with a definite or probable diagnosis of PBC.
Drug(s): Setanaxib
Interested in this study? Please contact the coordinator below:
Kelsey Green
greenke@iu.edu
(317) 278-9292
Zydus PBC
Enrolling: Yes
Principle Investigator: Raj Vuppalanchi, MD
Duration: 26 weeks
Patient Population: Non-cirrhotic
Drug(s): Oral Saroglitazar
Interested in this study? Please contact the coordinator below:
Mandy Cruz
mandcruz@iu.edu
(317) 278-6215
Closed Primary Biliary Cholangitis Studies
-
Intercept 302 - PBCEnrolling: No
Principle Investigator: Raj Vuppalanchi, MD
Duration: Upwards 6 - 8 years.
Patient Population: PBC with total Bili > ULN and ≤3x ULN or ALP >5x ULN
Drug(s): Obeticholic Acid tablet or placebo
-
PBC Itch
Enrolling: No
Principle Investigator: Craig Lammert, MD
Duration: 1 visit
Patient Population: PBC/Pre-Transplant and history of no/minimal itch or severe itch.